Vanguard Group
CRNX icon

Vanguard Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vanguard Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$425M Sell
9,135,504
-34,625
-0.4% -$1.54M 0.01% 1153
2025
Q3 		$382M Sell
9,170,129
-86,003
-0.9% -$2.75M 0.01% 1213
2025
Q2 		$266M Sell
9,256,132
-55,468
-0.6% -$1.71M ﹤0.01% 1366
2025
Q1 		$312M Buy
9,311,600
+222,209
+2% +$8.3M 0.01% 1253
2024
Q4 		$465M Buy
9,089,391
+2,801,736
+45% +$157M 0.01% 1081
2024
Q3 		$321M Buy
6,287,655
+1,773,177
+39% +$91.5M 0.01% 1290
2024
Q2 		$202M Buy
4,514,478
+939,402
+26% +$43.4M ﹤0.01% 1491
2024
Q1 		$167M Buy
3,575,076
+72,624
+2% +$2.84M ﹤0.01% 1616
2023
Q4 		$125M Buy
3,502,452
+95,417
+3% +$2.93M ﹤0.01% 1744
2023
Q3 		$101M Buy
3,407,035
+674,301
+25% +$13.9M ﹤0.01% 1806
2023
Q2 		$49.2M Buy
2,732,734
+39,672
+1% +$791K ﹤0.01% 2190
2023
Q1 		$43.3M Buy
2,693,062
+306,675
+13% +$5.68M ﹤0.01% 2239
2022
Q4 		$43.7M Buy
2,386,387
+29,740
+1% +$524K ﹤0.01% 2249
2022
Q3 		$46.3M Sell
2,356,647
-87,867
-4% -$1.79M ﹤0.01% 2223
2022
Q2 		$45.6M Buy
2,444,514
+345,201
+16% +$6.89M ﹤0.01% 2241
2022
Q1 		$46.1M Buy
2,099,313
+2,415
+0.1% +$48.9K ﹤0.01% 2342
2021
Q4 		$59.6M Buy
2,096,898
+421,017
+25% +$10.4M ﹤0.01% 2254
2021
Q3 		$35.3M Buy
1,675,881
+173,044
+12% +$3.62M ﹤0.01% 2551
2021
Q2 		$28.3M Buy
1,502,837
+338,920
+29% +$5.96M ﹤0.01% 2661
2021
Q1 		$17.8M Buy
1,163,917
+11,659
+1% +$181K ﹤0.01% 2847
2020
Q4 		$16.3M Buy
1,152,258
+71,160
+7% +$991K ﹤0.01% 2740
2020
Q3 		$16.9M Buy
1,081,098
+62
+0% +$948 ﹤0.01% 2541
2020
Q2 		$18.9M Buy
1,081,036
+572,819
+113% +$9.77M ﹤0.01% 2455
2020
Q1 		$7.47M Buy
508,217
+4,216
+0.8% +$86.4K ﹤0.01% 2757
2019
Q4 		$12.6M Sell
504,001
-100
-0% -$1.9K ﹤0.01% 2743
2019
Q3 		$7.58M Sell
504,101
-438
-0.1% -$8.52K ﹤0.01% 2963
2019
Q2 		$12.6M Buy
504,539
+52,327
+12% +$1.3M ﹤0.01% 2727
2019
Q1 		$10.3M Buy
452,212
+179,489
+66% +$4.41M ﹤0.01% 2809
2018
Q4 		$8.18M Buy
272,723
+24,800
+10% +$698K ﹤0.01% 2863
2018
Q3 		$7.1M Buy
+247,923
New +$7.36M ﹤0.01% 3098

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's CRNX Position: Q4 2025 in Review

Vanguard Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 0.38% in Q4 2025, selling an estimated $1.54M and leaving 9,135,504 shares worth $425M. The position accounts for 0.01% of the portfolio, ranked #1153.

Vanguard Group first reported a position in CRNX in Q3 2018 and has held it in 30 quarters since. The position peaked at $465M in Q4 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Vanguard Group held 9,135,504 shares of Crinetics Pharmaceuticals worth $425M as of Q4 2025.
  • Vanguard Group sold 34,625 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $1.54M.
  • Crinetics Pharmaceuticals made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1153 holding.
  • Vanguard Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
  • Vanguard Group's Crinetics Pharmaceuticals position peaked at $465M in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.